Amneal Pharmaceuticals, Inc. Files Definitive Proxy Statement (DEF 14A)

Ticker: AMRX · Form: DEF 14A · Filed: Mar 22, 2024 · CIK: 1723128

Sentiment: neutral

Topics: DEF 14A, Proxy Statement, Amneal Pharmaceuticals, Corporate Governance, Executive Compensation

TL;DR

<b>Amneal Pharmaceuticals, Inc. has filed its Definitive Proxy Statement (DEF 14A) for the fiscal year ending December 31, 2023.</b>

AI Summary

Amneal Pharmaceuticals, Inc. (AMRX) filed a Proxy Statement (DEF 14A) with the SEC on March 22, 2024. Filing Type: DEF 14A (Definitive Proxy Statement). Reporting Period: Fiscal year ended December 31, 2023. Filed As Of Date: March 22, 2024. Company Name: Amneal Pharmaceuticals, Inc. IRS Number: 000000000.

Why It Matters

For investors and stakeholders tracking Amneal Pharmaceuticals, Inc., this filing contains several important signals. This filing provides detailed information regarding the company's annual meeting, executive compensation, and other corporate governance matters. Shareholders can review proposals, director nominations, and voting procedures outlined in this document.

Risk Assessment

Risk Level: — Amneal Pharmaceuticals, Inc. shows moderate risk based on this filing. The filing is a routine DEF 14A, indicating standard corporate disclosures rather than significant new events or financial distress.

Analyst Insight

Review the executive compensation details and any shareholder proposals to understand potential impacts on corporate strategy and governance.

Key Numbers

Key Players & Entities

FAQ

When did Amneal Pharmaceuticals, Inc. file this DEF 14A?

Amneal Pharmaceuticals, Inc. filed this Proxy Statement (DEF 14A) with the SEC on March 22, 2024.

What is a DEF 14A filing?

A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by Amneal Pharmaceuticals, Inc. (AMRX).

Where can I read the original DEF 14A filing from Amneal Pharmaceuticals, Inc.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Amneal Pharmaceuticals, Inc..

What are the key takeaways from Amneal Pharmaceuticals, Inc.'s DEF 14A?

Amneal Pharmaceuticals, Inc. filed this DEF 14A on March 22, 2024. Key takeaways: Filing Type: DEF 14A (Definitive Proxy Statement). Reporting Period: Fiscal year ended December 31, 2023. Filed As Of Date: March 22, 2024.

Is Amneal Pharmaceuticals, Inc. a risky investment based on this filing?

Based on this DEF 14A, Amneal Pharmaceuticals, Inc. presents a moderate-risk profile. The filing is a routine DEF 14A, indicating standard corporate disclosures rather than significant new events or financial distress.

What should investors do after reading Amneal Pharmaceuticals, Inc.'s DEF 14A?

Review the executive compensation details and any shareholder proposals to understand potential impacts on corporate strategy and governance. The overall sentiment from this filing is neutral.

How does Amneal Pharmaceuticals, Inc. compare to its industry peers?

Amneal Pharmaceuticals operates in the pharmaceutical preparations industry, focusing on the development, manufacturing, and distribution of generic and specialty pharmaceutical products.

Are there regulatory concerns for Amneal Pharmaceuticals, Inc.?

The filing is a DEF 14A, a standard SEC filing required for public companies to solicit proxies from shareholders for annual meetings.

Industry Context

Amneal Pharmaceuticals operates in the pharmaceutical preparations industry, focusing on the development, manufacturing, and distribution of generic and specialty pharmaceutical products.

Regulatory Implications

The filing is a DEF 14A, a standard SEC filing required for public companies to solicit proxies from shareholders for annual meetings.

What Investors Should Do

  1. Analyze executive compensation packages for key personnel like Chirag Patel and Chintu Patel.
  2. Review any shareholder proposals and the company's recommendations.
  3. Note the dates for the annual meeting and proxy voting deadlines.

Year-Over-Year Comparison

This is a DEF 14A filing, which is a routine disclosure and does not represent a change from previous filings of the same type.

Filing Stats: 4,418 words · 18 min read · ~15 pages · Grade level 19.3 · Accepted 2024-03-22 08:01:10

Filing Documents

Executive Compensation Clawback Policy

Executive Compensation Clawback Policy 39 Stock Ownership Guidelines for Executive Officers 40 Anti-Hedging Policy 40 Report of the Compensation Committee 40 Summary Compensation Table 41 Grants of Plan Based Awards in 2023 42 Outstanding Equity Awards at December 31, 2023 43 2023 Option Exercises and Stock Vested 44 Management Employment & Separation Agreements 44 Severance Plan 46 Potential Payments Upon Termination or Change in Control 47 Pay Ratio Disclosure 49 Pay Versus Performance Disclosure 50 Description of Relationship Between PEO and Non-PEO NEO Compensation Actually Paid and Company Total Shareholder Return ("TSR") 52 Description of Relationship Between PEO and Non-PEO NEO Compensation Actually Paid and Net Income 53 Description of Relationship Between PEO and Non-PEO NEO Compensation Actually Paid and Adjusted EBITDA 54 Tabular List of Most Important Financial Performance Measures 54 Proposal 2 Advisory Vote on Executive Compensation 55 Introduction 55 Required Vote 55 Recommendation of the Board of Directors 55 Security 56 Beneficial Ownership 56 Certain Related Parties and Related Party Transactions 58 Review and Approval of Related Party Transactions 58 Related Party Transactions 58 Report of the Audit Committee 64 Proposal 3 Appointment of Independent Registered Public Accounting Firm 65 Introduction 65 Independent Registered Public Accounting Firm Fees 65 Required Vote 66 Recommendation of the Board of Directors 66 Back to Contents Other Matters 67 About the Meeting 68 Additional Information 72 Stockholder Proposals for Inclusion in Our 2025 Annual Meeting Proxy 72 Director Nominations and Other Proposals to Be Presented at Our 2025 Annual Meeting 72 Householding 72 Appendix A Non-GAAP Financial Measures 73 Non-GAAP Financial Measures 73 Reconciliatio

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on Read The Filing